Sentence examples for discontinuation points from inspiring English sources

It should be noted that the graph is computed by a piecewise linear model, giving rise to distinct discontinuation points that do not reflect a similar clinical effect of the covariate.

The NOQ is used to appraise quality in terms of population representativeness (1 point), measurement of outcome (i.e. discontinuation, 3 points), within population comparability (2 points) and adequacy of follow-up (i.e. completion rates, 1 point, only applicable in longitudinal studies).

At treatment discontinuation, emergent point mutations were less common among bosutinib [ n = 4 (6%)] versus imatinib patients [ n = 10 (18%); Table  III].

The balance of risks and benefits may warrant discontinuation at different points during the disease course.

Adherence has three components: initiation (the time point of first dose), execution (the extent to which the participant's product use corresponds to the instructed regimen), and discontinuation (the time point when the participant stops using the product).

Person-time follow-up started on 1 January 2004 and ended with the first occurrence of any of the defined nonfatal end points, death, discontinuation of Kaiser membership or pharmacy benefits (discontinuation defined as a gap of at least 3 months in coverage), or the end of our 4-year observation window (31 December 2007).

ProgrammableWeb in its coverage of the discontinuation of Microsoft Popfly points back to a February 2008 article in the NY Times, in which the newspaper talks about Montgomery and Popfly in a positive light, with the product manager being lauded as "an example of how it just might be possible for someone to teach dinosaurs to dance".

This workflow can be easily integrated into clinical studies, because it enables several points of discontinuation without loss of information.

17 Methods of trials of spontaneous breathing and the lower parameters stated by authors as end points before discontinuation or extubation varied greatly among trials.

All assessments were performed at the end of the treatment period at week 24 or at the point of discontinuation for patients who prematurely withdrew from the study.

The HONOR study and RRR study indicated that "deep remission" is required to successfully discontinue bDMARDs in established RA patients; DAS28-ESR cut-off point at discontinuation was 1.98 achieving remission at week 52 in the adalimumab withdrawal group and 2.22 for achieving LDA at week 52 in the infliximab-free group [ 6– 8].